Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31311153 | 0.89 | MPL (0.49) | MPLALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL25280365 | 0.87 | MPL (0.66) | MPLALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL30464966 | 0.87 | MPL (0.66) | MPLALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL25247416 | 0.86 | MPL (0.69) | MPLALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL31156391 | 0.86 | MPL (0.69) | MPLALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL31311302 | 0.86 | MPL (0.47) | MPLALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL31311373 | 0.80 | MPL (0.57) | MPLALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL5310112 | 0.78 | CYP1A2 (0.61) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL25695456 | 0.77 | MPL (0.55) | MPLALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL23610359 | 0.77 | MPL (0.57) | MPLALDH1A1KDM4ECYP3A4ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Cadrenal Therapeutics, Inc. | 2025-02-27 | — | — | US | disclosed |
| WO-2024264032-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-119013013-A | Compositions and methods of use for treating 12-lipoxygenase (12-LOX) -mediated diseases | 维拉洛斯治疗公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023122494-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | ALOX12, LOX, ALOX15 | MPL 286/4885ALDH1A1 745/4885KDM4E 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.